<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547912" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547912/" /><meta name="ncbi_pagename" content="Fosfomycin - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Fosfomycin - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Fosfomycin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/02/06" /><meta name="citation_pmid" content="31643248" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547912/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Fosfomycin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/02/06" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547912/" /><meta name="description" content="Fosfomycin is an orally available, broad spectrum antibiotic used largely for treatment of uncomplicated urinary tract infections. Fosfomycin is associated with a low rate of transient serum enzyme during therapy and with rare cases of clinically apparent acute liver injury with jaundice." /><meta name="og:title" content="Fosfomycin" /><meta name="og:type" content="book" /><meta name="og:description" content="Fosfomycin is an orally available, broad spectrum antibiotic used largely for treatment of uncomplicated urinary tract infections. Fosfomycin is associated with a low rate of transient serum enzyme during therapy and with rare cases of clinically apparent acute liver injury with jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547912/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Fosfomycin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547912/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A57900467A9810000000001F60099.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK547912_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK547912_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Foscarnet/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Fosinopril/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547912_"><span class="title" itemprop="name">Fosfomycin</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 6, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Fosfomycin.OVERVIEW"><h2 id="_Fosfomycin_OVERVIEW_">OVERVIEW</h2><div id="Fosfomycin.Introduction"><h3>Introduction</h3><p>Fosfomycin is an orally available, broad spectrum antibiotic used largely for treatment of uncomplicated urinary tract infections. Fosfomycin is associated with a low rate of transient serum enzyme during therapy and with rare cases of clinically apparent acute liver injury with jaundice.</p></div><div id="Fosfomycin.Background"><h3>Background</h3><p>Fosfomycin (fos' foe mye. sin) is an oral, broad spectrum bactericidal antibiotic that is typically used as a single, large oral dose to treat acute cystitis. Fosfomycin (also known as phosphomycin) is a natural product of Streptomyces fradiae that acts by inactivation of a bacterial enzyme necessary for cell wall synthesis. Fosfomycin has a unique structure (an analogue of phosphoenolpyruvate) and is structurally unrelated to other antibiotics. It has activity against both gram-positive and gram-negative bacteria and is excreted largely unchanged and in its active form in the urine, making it useful for treatment of urinary tract infections. Antibacterial resistance is, however, frequent with prolonged use. Fosfomycin was approved for use in the United States in 1997 and current indications are for uncomplicated urinary tract infections caused by susceptible organisms. Fosfomycin is available under the commercial name Monurol in a sachet of 3 grams and is recommended as a single dose. Intravenous formulations of fosfomycin have been used in combination with carbapenems or aminoglycosides as therapy of multidrug resistant bacterial organisms such as methicillin-resistant Staphyloccocus aureus (MRSA), but it has yet to be approved for this use in the United States. The intravenous formulation is generally given in 1 to 2 gram amounts every 6 hours for 3 to 28 days. Oral fosfomycin is well tolerated; common side effects may include diarrhea, nausea, headache and fungal vaginitis. Rare, but potentially serious adverse events include allergic reactions, anaphylaxis and toxic megacolon.</p></div><div id="Fosfomycin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Serum aminotransferase elevations occur in a small proportion of patients after a single oral dose of fosfomycin (1-2%), but at rates similar to those with comparator antibiotics. Nevertheless, serum enzyme elevations are mentioned as potential adverse events in the product label for fosfomycin. In addition, a small number of cases of clinically apparent liver injury attributed to fosfomycin have been published. The time to onset has been short, within one week of a single oral dose or within the first week of intravenous therapy, and the pattern of liver enzyme elevations has been mixed or hepatocellular. The injury has typically been mild and self-limited, and no cases of fatal acute liver failure, chronic hepatitis or vanishing bile duct syndrome have been convincingly linked to fosfomycin. The number of cases described has been too few to establish a typical clinical pattern, but immunoallergic features and autoimmune markers appear to be uncommon.</p><p>Likelihood score: D (possible rare cause of clinically apparent liver injury).</p></div><div id="Fosfomycin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the liver injury due to fosfomycin is unknown, but is likely to be immunologically mediated. Fosfomycin has minimal hepatic metabolism (mostly glucuronidation), and drug-drug interactions with it are not expected.</p></div><div id="Fosfomycin.Outcome_and_Management"><h3>Outcome and Management</h3><p>The severity of the liver injury linked to fosfomycin has ranged from transient, asymptomatic serum enzyme elevations to clinically apparent hepatitis. Severe but not fatal instances of acute hepatitis have been reported. In one publication, reexposure to fosfomycin after clinically apparent liver injury led to a rapid recurrence. Fosfomycin has a unique chemical structure unlike other antibiotics, and there is evidence for cross sensitivity to hepatic injury between fosfomycin and other antimicrobial agents.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/">Antiinfective Agents</a></p></div></div><div id="Fosfomycin.CASE_REPORT"><h2 id="_Fosfomycin_CASE_REPORT_">CASE REPORT</h2><div id="Fosfomycin.Case_1._Acute_hepatitis_attri"><h3>Case 1. Acute hepatitis attributed to fosfomycin.</h3><p>[Modified from: Matsumori A, Yoneda S, Kobayashi Y, Takeda K, Andoh M, Yamane Y, Nishimura K, et al. [A case of acute severe hepatitis induced by fosfomycin]. Nihon Shokakibyo Gakkai Zasshi 2005; 102: 1207-11. Japanese. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16180681" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 30 year old, previously healthy man with an upper respiratory infection developed fever, fatigue, and jaundice a few days after a single, oral dose of fosfomycin. He had no history of liver disease, alcohol abuse or drug allergies. He was not taking other medications except for cold remedies. He had fever, but no rash or lymphadenopathy. Laboratory tests showed a total bilirubin of 6.5 mg/dL (direct 3.5 mg/dL), <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 558 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 442 U/L, alkaline phosphatase 649 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.gamma-glutamyl-transpeptidase-ggt-/">GGT</a> 192 U/L and a prothrombin index of 44% (roughly equivalent to an INR of 1.7). He was admitted for observation and management (Table). Tests for hepatitis A, B and C were negative as were tests for CMV and EBV infection. ANA and AMA were negative and IgG levels were minimally elevated (1714 mg/dL). An abdominal ultrasound and enhanced CT showed evidence of severe liver necrosis with atrophy. Within the next few days, he developed asterixis with a worsening of prothrombin time and hyperammonemia (112 &#x003bc;g/dL). He was treated with plasma exchange given infusions of glucagon and insulin, whereupon he began to improve. A liver biopsy done 6 weeks after presentation showed spotty necrosis, inflammation and regeneration. He was discharged after 42 days in the hospital. All laboratory tests were normal when he was seen in follow up, 4 months after onset.</p><div id="Fosfomycin.Key_Points"><h4>Key Points</h4><div id="Fosfomycin.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547912/table/Fosfomycin.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Fosfomycin.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Fosfomycin.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Fosfomycin, single oral dose</td></tr></thead><tbody><tr><th headers="hd_h_Fosfomycin.T1_1_1_1_1" id="hd_b_Fosfomycin.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Fosfomycin.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Mixed (R=~2.8)</td></tr><tr><th headers="hd_h_Fosfomycin.T1_1_1_1_1" id="hd_b_Fosfomycin.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Fosfomycin.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">4+ (jaundice, hospitalization and features of hepatic failure)</td></tr><tr><th headers="hd_h_Fosfomycin.T1_1_1_1_1" id="hd_b_Fosfomycin.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Fosfomycin.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">3 days</td></tr><tr><th headers="hd_h_Fosfomycin.T1_1_1_1_1" id="hd_b_Fosfomycin.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Fosfomycin.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Within 4 months</td></tr><tr><th headers="hd_h_Fosfomycin.T1_1_1_1_1" id="hd_b_Fosfomycin.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Fosfomycin.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Over-the-counter cold remedies</td></tr></tbody></table></div></div></div><div id="Fosfomycin.Laboratory_Values"><h4>Laboratory Values</h4><div id="Fosfomycin.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547912/table/Fosfomycin.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Fosfomycin.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting/Stopping</th><th id="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>* (U/L)</th><th id="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Prothrombin Index*</th><th id="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>* (mg/dL)</th><th id="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">558</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">44%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">6.5</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">540</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">40%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">6.5</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Plasma exchange</td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">480</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">35%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">6.4</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Plasma exchange</td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">220</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">30%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">3.5</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Plasma exchange</td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">130</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">33%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">3.0</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">160</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">37%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">3.8</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">20 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">150</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">45%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">2.0</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">30 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">100</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">75%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">1.4</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">42 days</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">50</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">80%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Liver biopsy, discharged</td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 months</td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">95%</td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">0.8</td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Fosfomycin.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><b>Normal</b></td><td headers="hd_h_Fosfomycin.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><b>Not Given</b></td><td headers="hd_h_Fosfomycin.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003e;80%</b></td><td headers="hd_h_Fosfomycin.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Fosfomycin.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>*Values estimated from Figure 3.</p></div><div id="Fosfomycin.Comment"><h4>Comment</h4><p>A young man developed a severe hepatitis a few days after receipt of a single, large oral dose of fosfomycin for a suspected upper respiratory infection. The pattern of liver enzyme elevations was "mixed", but the course resembled acute liver failure. Other causes of liver disease were adequately ruled out, although tests for hepatitis E and a few rare opportunistic viral infections were not done. Evidence of hepatic failure included prolongation of prothrombin time, hyperammonemia, asterixis and CT and ultrasound evidence of severe hepatic necrosis. The few other reported cases of clinically apparent liver injury from fosfomycin have been self-limited, with mild jaundice and a hepatocellular pattern of serum enzyme elevations. Fosfomycin has been used extensively abroad, in Europe and Asia, but has had limited use in the United States. As might be expected, cases of drug induced liver injury from fosfomycin have been reported from Japan, China and Europe, but not the United States. [Help in the translation of this case report was kindly provided by Dr. Saturo Saito.]</p></div></div></div><div id="Fosfomycin.PRODUCT_INFORMATION"><h2 id="_Fosfomycin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Fosfomycin.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Fosfomycin &#x02013; Monurol&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=fluoxetine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Fosfomycin.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Fosfomycin_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Fosfomycin.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547912/table/Fosfomycin.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Fosfomycin.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Fosfomycin.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Fosfomycin.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Fosfomycin.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Fosfomycin.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Fosfomycin.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Fosfomycin</td><td headers="hd_h_Fosfomycin.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134994616" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">23155-02-4</a></td><td headers="hd_h_Fosfomycin.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C3-H7-O4-P</td><td headers="hd_h_Fosfomycin.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK547912/bin/fosfomycin_structure.jpg" alt="chemical structure for Fosfomycin" /></div></td></tr></tbody></table></div></div></div><div id="Fosfomycin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Fosfomycin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 06 February 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Fosfomycin.R1">Zimmerman HJ. Hepatic injury from the treatment of infectious and parasitic diseases. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 589-637.<div><i>(Expert review of hepatotoxicity of antibiotics published in 1999 does not mention fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R2">Moseley RH. Antibacterial and Antifungal Agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013. p. 463-81.<div><i>(Review of hepatotoxicity of antibacterial medications; does not discuss fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R3">de Jong Z, Pontonnier F, Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int 1991; 46: 344-8.  [<a href="/pubmed/1926651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1926651</span></a>]<div><i>(Among 63 patients given fosfomycin or norfloxacin for uncomplicated urinary tract infections, efficacy was similar, but side effects were fewer and of shorter duration with fosfomycin; one patient on norfloxacin, but none on fosfomycin had "change in hepatic function").</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R4">Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. Pharm World Sci 1993; 15: 257-62.  [<a href="/pubmed/8298585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8298585</span></a>]<div><i>(Among 231 women with urinary tract infections managed in general practices in the Netherlands who were treated with a single dose of fosfomycin or 7 days of nitrofurantoin, clinical cure rates were similar and side effects were generally mild and self-limited; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R5">Mayama T, Yokota M, Shimatani I, Ohyagi H. Analysis of oral fosfomycin calcium (Fosmicin) side-effects after marketing. Int J Clin Pharmacol Ther Toxicol 1993; 31: 77-82.  [<a href="/pubmed/8458680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8458680</span></a>]<div><i>(Analysis of spontaneous reports of adverse events associated with the first six years of clinical use of fosfomycin capsules from 28,238 patients in Japan found 2.9% frequency of gastrointestinal symptoms and 0.2% rate of "disorder of liver and bile duct", but no case associated with jaundice).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R6">Elhanan G, Tabenkin H, Yahalom R, Raz R. Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women. Antimicrob Agents Chemother 1994; 38: 2612-4.  [<a href="/pmc/articles/PMC188250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC188250</span></a>] [<a href="/pubmed/7872756" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7872756</span></a>]<div><i>(Among 112 women with urinary tract infections treated with either cephalexin or fosfomycin, efficacy was similar in the two groups and there were no significant adverse events attributed to fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R7">Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56.  [<a href="/pubmed/9098664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9098664</span></a>]<div><i>(Review of the mechanism of action, efficacy and safety of fosfomycin mentions that reported serious adverse events included angioedema, asthma, cholestatic jaundice, hepatic necrosis, toxic megacolon and optic neuritis).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R8">Fosfomycin for urinary tract infections. Med Lett Drugs Ther 1997; 39 (1005): 66-8.  [<a href="/pubmed/9255237" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9255237</span></a>]<div><i>(Concise review of the activity, efficacy, side effects and costs of fosfomycin for urinary tract infections shortly after its approval for this use in the US; no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R9">Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998; 10: 39-47.  [<a href="/pubmed/9624542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9624542</span></a>]<div><i>(Among 547 women with urinary tract infections treated by general practitioners with either a single oral dose of fosfomycin or a 5 day course of trimethoprim, efficacy was similar; side effects were not discussed).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R10">Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21: 1864-72.  [<a href="/pubmed/10890258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10890258</span></a>]<div><i>(Among 749 women with urinary tract infections treated with a single oral dose of fosfomycin or a 5 day course of nitrofurantoin, response rates and adverse event rates were similar and there were "no clinically significant changes in biochemical or hematologic values").</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R11">Durupt S, Josserand RN, Sibille M, Durieu I. Acute, recurrent fosfomycin-induced liver toxicity in an adult patient with cystic fibrosis. Scand J Infect Dis 2001; 33: 391-2.  [<a href="/pubmed/11440232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11440232</span></a>]<div><i>(30 year old woman with cystic fibrosis developed abdominal pain 4 days after starting intravenous fosfomycin [12 g daily] and imipenem [bilirubin not given, ALT 921 U/L, GGT 214 U/L], which resolved a month after antibiotics were stopped and recurred 3 days after starting cefepim and fosfomycin [ALT 163 U/L, GGT 79 U/L], resolving within 1 week of stopping and recurring with a third course of fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R12">Matsumori A, Yoneda S, Kobayashi Y, Takeda K, Andoh M, Yamane Y, Nishimura K, et al. [A case of acute severe hepatitis induced by fosfomycin]. Nihon Shokakibyo Gakkai Zasshi 2005; 102: 1207-11. Japanese.  [<a href="/pubmed/16180681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16180681</span></a>]<div><i>(30 year old man with an upper respiratory tract infection developed jaundice 3 days after a single oral dose of fosfomycin [bilirubin 6.5 mg/dL, ALT 558 U/L, Alk P 649 U/L, prothrombin index 44%], with a severe course, but resolving within 4 months: Case 1).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R13">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US between 2004 and 2008, more than 100 agents were implicated and the most commonly implicated class of agents was antibiotics, but no case was attributed to fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R14">Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced liver disease: an 8-year study of patients from one gastroenterological department. J Dig Dis 2009; 10: 195-200.  [<a href="/pubmed/19659787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19659787</span></a>]<div><i>(30 cases of drug induced liver injury were seen at a single large hospital in Shanghai between 2000 and 2007, including one case in a 50 year old man who developed mild hepatitis [bilirubin 2.5 mg/dL, ALT 12.8 times and Alk P 1.9 times ULN] within 3 days of starting fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R15">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R16">Falagas ME, Vouloumanou EK, Togias AG, Karadima M, Kapaskelis AM, Rafailidis PI, Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862-77.  [<a href="/pubmed/20587612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20587612</span></a>]<div><i>(Systematic review of 27 controlled trials of fosfomycin for urinary tract infections mentions diarrhea and headache as complications, but does not mention ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R17">Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, Yang B, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 2013; 3: e004157.  [<a href="/pmc/articles/PMC3855495/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3855495</span></a>] [<a href="/pubmed/24309172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24309172</span></a>]<div><i>(Among 356 Chinese patients with acute cystitis who received three 3 g doses of fosfomycin, side effects included diarrhea [5%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R18">Del R&#x000ed;A, Gasch O, Moreno A, Pe&#x000f1;, Cuquet J, Soy D, Mestres CA, et al.; FOSIMI Investigators. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: A multicenter clinical trial. Clin Infect Dis 2014; 59: 1105-12.  [<a href="/pubmed/25048851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25048851</span></a>]<div><i>(Among 16 patients with complicated MRSA infections treated with the combination of imipenem and fosfomycin [2 g intravenously every 6 hours for 4 to 75 days], blood cultures were negative at 72 hours in all patients and no breakthrough infections occurred; side effects included sodium overload in 3 patients and leukopenia in one; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R19">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7. <a href="https://www.ncbi.nlm.nih.gov/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 cases [36%] were attributed to antibiotics, but none to fosfomycin).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R20">Iarikov D, Wassel R, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the literature and analyses of the FDA adverse event reporting System database. Infect Dis Ther 2015; 4: 433-58.  [<a href="/pmc/articles/PMC4675770/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4675770</span></a>] [<a href="/pubmed/26437630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26437630</span></a>]<div><i> (Systematic review of the literature and the FDA reporting sytem for adverse events related to fosfomycin, found ALT elevations occurring in similar proportions of patients treated with fosfomycin (oral or iv) as with comparator antibiotics [&#x0003c;1% vs &#x0003c;1%] and that only 5 instances of hepatitis in patients receiving fosfomycin have been reported to the FDA, suggesting that liver injury is quite rare even with parenteral therapy).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R21">Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, Jones N. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis 2016; 16: 556.  [<a href="/pmc/articles/PMC5057270/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5057270</span></a>] [<a href="/pubmed/27729016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27729016</span></a>]<div><i> (Among 75 patients treated for 151 episodes of urinary tract infections, adverse events were uncommon; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Fosfomycin.R22">Jacobson S, Junco Noa L, Ahmed S, Wallace MR. Efficacy and wafety of oral fosfomycin for urinary tract infections in hospitalized patients. Antimicrob Agents Chemother 2016; 60: 1952.  [<a href="/pmc/articles/PMC4775933/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4775933</span></a>] [<a href="/pubmed/26921414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26921414</span></a>]<div><i> (Among 71 patients treated with oral fosfomycin for urinary tract infections, cure rate was 83% and adverse event rate 4%, which were mostly nausea and vomiting; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547912</span><span class="label">PMID: <a href="/pubmed/31643248" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643248</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Foscarnet/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Fosinopril/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK547912&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK547912/?report=reader">PubReader</a></li><li><a href="/books/NBK547912/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK547912" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK547912" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Fosfomycin. [Updated 2018 Feb 6].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK547912/pdf/Bookshelf_NBK547912.pdf">PDF version of this page</a> (124K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(fluoxetine)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Fosfomycin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=fluoxetine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Fosfomycin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4855080" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4855080" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4855080" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30742381" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Efficiency of fosfomycin trometamol for treatment of acute uncomplicated cystitis].</a><span class="source">[Urologiia. 2018]</span><div class="brieflinkpop offscreen_noflow">[Efficiency of fosfomycin trometamol for treatment of acute uncomplicated cystitis].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Urologiia. 2018 Dec; (6):70-75. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9098664" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.</a><span class="source">[Drugs. 1997]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Patel SS, Balfour JA, Bryson HM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 1997 Apr; 53(4):637-56. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31535800" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Experience of using the antibacterial drug Fosfomycin Esparma for the treatment of acute uncomplicated cystitis in women].</a><span class="source">[Urologiia. 2019]</span><div class="brieflinkpop offscreen_noflow">[Experience of using the antibacterial drug Fosfomycin Esparma for the treatment of acute uncomplicated cystitis in women].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Aboyan IA, Orlov YN, Voloshina OA, Orlov NV, Pavlov DS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Urologiia. 2019 Sep; (4):20-25. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24669389" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recurrent uncomplicated cystitis in women: allowing patients to self-initiate antibiotic therapy.</a><span class="source">[Prescrire Int. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Recurrent uncomplicated cystitis in women: allowing patients to self-initiate antibiotic therapy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Prescrire Int. 2014 Feb; 23(146):47-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27737907" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fosfomycin for UTIs.</a><span class="source">[Drug Ther Bull. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fosfomycin for UTIs.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drug Ther Bull. 2016 Oct; 54(10):114-117. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643248" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643248" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604683bd739e6e7637e624f5">Fosfomycin - LiverTox</a><div class="ralinkpop offscreen_noflow">Fosfomycin - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:06:22-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8A57900467A9810000000001F60099&amp;ncbi_session=CE8A579004683BD1_0502SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547912%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK547912&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK547912/&amp;ncbi_pagename=Fosfomycin - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A579004683BD1_0502SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>